Influence of Blood Coagulation Factor XIII and FXIII Val34Leu on Plasma Clot Formation Measured by Thrombelastography

      Abstract

      Blood coagulation factor XIII (FXIII) plays an important role in the final stage of the blood coagulation process. Thrombelastography (TEG) enables global assessment of the hemostatic function. The present study tested for the first time the specificity and sensitivity of the rotation thrombelastography (ROTEG: rotation thrombelastography) method for the influence of FXIII and the FXIIIVal34Leu polymorphism on thrombelastograms measured in citrated plasma. Three thrombelastographic parameters were determined in (a) citrated pool plasma, (b) FXIII-deficient plasma, (c) different mixtures of both, and (d) in 60 plasma samples genotyped for FXIIIVal34Leu. Thrombelastograms from FXIII-deficient plasma were significantly smaller than those from pool plasma (8 mm vs. 20.9 mm). Increasing amounts of pool plasma added to FXIII-deficient plasma led to an increase in maximum clot firmness (MCF). FXIIIVal34Leu showed an influence on clot formation time (CFT) values, which decreased with increasing number of Leu alleles. The difference between the wild type and the homozygote mutant genotype was statistically significant (median 185.3 vs. 86.0 s, P=.031). ROTEG is a simple but effective method for the investigation of FXIII function in plasma. The ROTEG method has shown to be not only specific for the FXIII influence, as effects exclusively dependent on FXIII could be observed, but also sensitive, as already smallest amounts of FXIII could be detected. Additionally, the impact of a common genetic polymorphism on ROTEG could be shown for the first time.

      Keywords

      Abbreviations:

      CFT (clot formation time), CI (confidence interval), CT (clotting time), DNA (deoxyribonucleic acid), EDTA (ethylenediaminetetraacetic acid), ELISA (enzyme-linked immunosorbent assay), FXIII (factor XIII), MCF (maximum clot firmness), PAI-1 (plasminogen activator inhibitor type 1), PCR (polymerase chain reaction), RFLP (restriction fragment length polymorphism), ROTEG (rotation thrombelastography), TAFI (thrombin-activatable fibrinolysis inhibitor), TBS (Tris-buffered saline), TEG (thrombelastography)
      To read this article in full you will need to make a payment
      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ichinose A
        The physiology and biochemistry of factor XIII.
        in: 3rd ed. Haemostasis and thrombosis. vol. 1. Livingstone, Edinburg1994: 531-546
        • Sakata Y
        • Aoki N
        Cross-linking of α2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.
        J Clin Invest. 1980; 65: 290-297
        • Valnickova Z
        • Enghild JJ
        Human procarboxypeptidase U, or thrombin-activatable fibrinolysis inhibitor, is a substrate for transglutaminases.
        J Biol Chem. 1998; 273: 27220-27224
        • Kohler HP
        • Stickland MH
        • Ossei-Gerning N
        • Carter C
        • Mikkola H
        • Grant PJ
        Association of a common polymorphism in the factor XIII gene with myocardial infarction.
        Thromb Haemostasis. 1998; 79: 8-13
        • Wartiovaara U
        • Perola M
        • Mikkola H
        • Tötterman K
        • Savolainen V
        • Penttilä A
        • Grant PJ
        • Tikkanen MJ
        • Vartiainen E
        • Karhunen PJ
        • Peltonen L
        • Palotie A
        Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males.
        Atherosclerosis. 1999; 142: 295-300
        • Elbaz A
        • Poirier O
        • Canaple S
        • Chédru F
        • Cambien F
        • Amarenco P
        The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction.
        Blood. 2000; 95: 586-591
        • Kohler HP
        • Futers TS
        • Grant PJ
        Prevalence of three common polymorphisms in the A-subunit gene of factor XIII in patients with coronary artery disease.
        Thromb Haemostasis. 1999; 81: 511-515
        • Catto AJ
        • Kohler HP
        • Coore J
        • Mansfield MW
        • Stickland MH
        • Grant PJ
        Association of a common polymorphism in the factor XIII gene with venous thrombosis.
        Blood. 1999; 93: 906-908
        • Kohler HP
        • Grant PJ
        Role of factor XIII Val34Leu in cardiovascular disease.
        Q J Med. 1999; 92 (Review): 67-72
        • Kohler HP
        • Grant PJ
        Mechanisms of disease: plasminogen-activator inhibitor type 1 and coronary artery disease.
        N Engl J Med. 2000; 342: 1792-1801
        • Alhenc-Gelas M
        • Rény JL
        • Aubry ML
        • Aiach M
        • Emmerich J
        The FXIII Val 34 Leu mutation and the risk of venous thrombosis.
        Thromb Haemostasis. 2000; 84: 1117-1118
        • Trumbo TA
        • Maurer MC
        Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation.
        J Biol Chem. 2000; 275: 20627-20631
        • Ariëns RAS
        • Philippou H
        • Chandrasekaran N
        • Weisel JW
        • Lane DA
        • Grant PJ
        The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure.
        Blood. 2000; 96: 988-995
        • Hartert H
        Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren.
        Klin Wochenschr. 1948; 26: 577-583
      1. Wenker O, Wojciechowski Z, Sheinbaum R, Zisman E. Thrombelastography. Internet J Anesthesiol 1997; http://www.ispub.com/journals/IJA/Vol1N3/teg.htm. Published July 1, 1997; last updated January 28, 1999.

        • Chandler WL
        The thromboelastograph and the thromboelastograph technique.
        Semin Thromb Hemostasis. 1995; 21: 1-6
        • Traverso CI
        • Caprini JA
        • Arcelus JI
        The normal thromboelastogram and its interpretation.
        Semin Thromb Hemostasis. 1995; 21: 7-13
        • Caprini JA
        • Traverso CI
        • Arcelus JI
        Perspectives on thromboelastography.
        Semin Thromb Hemostasis. 1995; 21: 91-93
        • De Nicola P
        • Spreafico PL
        Studies on the evaluation of factor XIII (fibrin-stabilizing factor) by means of the MIA tolerance (visual and thrombelastographic technique).
        Hémostase. 1966; 6: 325-332
        • Abels J
        • Smit Sibinga CT
        • Meyler L
        Congenital hemorrhagic diathesis with deficiency of factor XIII. A case report and a family study.
        Thromb Diath Haemorrh. 1970; 23: 340-346
        • Francis JL
        The detection and measurement of factor XIII activity: a review.
        Med Lab Sci. 1980; 37: 137-147
        • McDonagh J
        • McDonagh RP
        • Delâge JM
        • Wagner RH
        Factor XIII in human plasma and platelets.
        J Clin Invest. 1969; 48: 940-946
        • Tyler HM
        Fibrin crosslinking demonstrated by thrombelastography.
        Thromb Diath Haemorrh. 1969; 22: 398-400
        • Calatzis A
        • Gödje O
        • Haas S
        • Fuchs A
        • Reichart B
        Erhöhung der Gerinnselfestigkeit vor und nach herzchirurgischen Eingriffen durch Zusatz von Faktor XIII in vitro.
        in: Egbring R Seitz R Wozniak Klinische Aspekte des Faktor-XIII Mangels. Diagnostik, klinische Relevanz, klinische Forschung. Karger, Basel1999: 55-62
        • Kangsadalampai S
        • Board PG
        The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity.
        Blood. 1998; 92: 2766-2770
        • Ariëns RAS
        • Kohler HP
        • Mansfield MW
        • Grant PJ
        Subunit antigen and activity levels of blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking and hypertension.
        Arterioscler, Thromb, Vasc Biol. 1999; 19: 2012-2016
        • Clauss A
        Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens.
        Acta Haematol. 1952; 17: 237-246
      2. Mikkola H. Molecular basis of coagulation factor XIII deficiency. Academic dissertation, University of Helsinki, Finland, 1997.

        • Kohler HP
        • Ariëns RAS
        • Whitaker P
        • Grant PJ
        A common coding polymorphism in the factor XIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity.
        Thromb Haemostasis. 1998; 80: 704
        • Schroeder V
        • Kohler HP
        Effect of factor XIII Val34Leu on α2-antiplasmin incorporation into fibrin.
        Thromb Haemostasis. 2000; 84: 1128-1130
        • Atwa AAA
        • Grant PJ
        • Ariëns RAS
        Effect of the FXIII Val34Leu polymorphism on the interaction between platelets and cross-linked fibrin.
        Thromb Haemostasis. 2001; (Supplement, July)
        • Lee AJ
        • Fowkes FG
        • Lowe GD
        • Connor JM
        • Rumley A
        Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study.
        Thromb Haemostasis. 1999; 81: 553-560
        • Girelli D
        • Russo C
        • Ferraresi P
        • Olivieri O
        • Pinotti M
        • Friso S
        • Manzato F
        • Mazzucco A
        • Bernardi F
        • Corrocher R
        Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease.
        N Engl J Med. 2000; 343: 774-780
        • Lane DA
        • Grant PJ
        Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease.
        Blood. 2000; 95 (Review): 1517-1532